What advancements have we witnessed in the field of immunotherapy for lung cancer and what does the future of this field look like? Find out in this article from Lung Cancer Management.
Browsing: Journals > Lung Cancer Management
In this case report the authors present systematic therapy as a multimodality tool in the management of patients with oligometastatic disease.
Discover more about how mutations in DNA repair genes could be exploited in favor of cancer therapy in lung cancer.
Oncogenic gene fusions of neurotrophic tyrosine kinase genes have been identified in solid tumors and studies have shown them to be associated with worse survival in all types of lung cancer – is there any potential in inhibitors of these genes in the disease?
This commentary article explores the potential role of DNA repair in lung cancer, covering disease susceptibility and therapy response.
How could novel therapeutic innovations – for example checkpoint inhibitors – be used to improve outcomes in potentially curable stage III non-small-cell lung cancer patients?
This article provides an overview of the toxicities associated with US FDA-approved targeted therapies for lung cancer in light of the increase in novel agents.
How are EGFR-TKIs utilized in the treatment of brain metastases in patients with NSCLC? This article reviews the use of these agents and compares them with other therapy modalities, such as WBRT.
This report details a case of pulmonary adenocarcinoma that demonstrated combined ALK translocation and copy number gain, providing clinical follow-up information including ALK inhibitor treatment responses.
This review summarizes the published evidence for the use of local therapy in the management of oligometastatic cancer, with a focus on SBRT and NSCLC.